| Drug General Information |
| Drug ID |
D02LCR
|
| Former ID |
DNC001444
|
| Drug Name |
Tiapride
|
| Drug Type |
Small molecular drug
|
| Indication |
Alcohol use disorders [ICD9: 303; ICD10:F10.2]
|
Approved |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C15H24N2O4S
|
| Canonical SMILES |
CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC
|
| InChI |
1S/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18)
|
| InChIKey |
JTVPZMFULRWINT-UHFFFAOYSA-N
|
| CAS Number |
CAS 51012-32-9
|
| PubChem Compound ID |
|
| PubChem Substance ID |
5650056, 8153358, 11111853, 11111854, 11335913, 11361152, 11364248, 11366810, 11369372, 11372631, 11374335, 11377534, 11462124, 11466244, 11467364, 11485038, 11485888, 11489337, 11491371, 11492593, 11495168, 14753076, 24278720, 29224512, 47365211, 47440279, 47662306, 47810769, 47885441, 48035146, 48259255, 48259256, 48416623, 49698930, 49876371, 50100350, 50104277, 57322792, 75320710, 85209867, 85788830, 90340591, 91722395, 92711448, 96025274, 103287107, 104309317, 114916115, 118307518, 124750253
|
| SuperDrug ATC ID |
N05AL03
|
| SuperDrug CAS ID |
cas=051012329
|
| Target and Pathway |
| Target(s) |
D(2) dopamine receptor |
Target Info |
Antagonist |
[2]
|
|---|
|
KEGG Pathway
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
| REF 2 | The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914. |
|---|
